Industrializing your manufacturing process
With small patient-scale batch sizes, centralized production using scale-up processes is no longer applicable and scale-out approaches become the norm for Autologous cell therapy manufacturing. Today, the cost of production still represents a major hurdle on the path to market. New technologies are needed that enable robust and cost-efficient manufacturing and yield replicable high quality medicines.
At Lonza, we are technology agnostic and as the most experienced cell therapy CDMO, we have experience using the majority of all technologies required for autologous cell therapy manufacturing, testing and release. In addition, we are also introducing proprietary technologies to address specific challenges or automation and digitalization of your manufacturing process, including:
- Electronic batch-records and manufacturing traceability with our MODA™-ES Platform
- Closed, automated manufacturing with our Cocoon® platform
- Standard unit operation platforms for a streamlined path into GMP manufacturing
A vein-to-vein network of partnerships to address the need for just-in-time manufacturing from Autologous cell therapies
Autologous cell therapies are at the forefront of the cell and gene therapy revolution. Cells from an individual patient are collected, processed ex vivo and then returned to the same patient as the most personalized treatment possible today.
This vein-to-vein journey brings a new need to pharmaceutical manufacturing to produce and deliver medicines to your patients in the shortest possible timelines, without any shelf-life. We refer to it as “just-in-time manufacturing”.
Our role as a manufacturing partner has evolved to integrate the entire supply-chain network around the manufacturing of our customers’ autologous cell therapies. We are fully connected and in sync with the fluctuations of patient demand.